PURPOSE: The prognosis of gastric cancer (GC) is poor, and the molecular pathogenesis players are vastly unknown. Surgery remains the primary option in GC treatment. The aim of this study was to investigate the impact of somatic CDH1 alterations in prognosis and survival of patients with GC. PATIENTS AND METHODS: A series of patients with sporadic and familial GC (diffuse and intestinal; n = 246) were analyzed for somatic CDH1 mutations, promoter hypermethylation, and loss of heterozygosity (LOH) by polymerase chain reaction sequencing. E-cadherin protein expression was determined by immunohistochemistry. Associations between molecular, clinicopathologic, and survival data were analyzed. RESULTS: CDH1 somatic alterations were found in approximately 30% of all patients with GC. Both histologic types of sporadic GC displayed LOH in 7.5%, mutations in 1.7%, and hypermethylation in 18.4% of patients. Primary tumors from hereditary diffuse GC, lacking germline CDH1 alterations, showed exclusively CDH1 promoter hypermethylation in 50% of patients. Familial intestinal GC (FIGC) tumors showed LOH in 9.4% and hypermethylation in 17.0%. CDH1 alterations did not associate with a particular pattern of E-cadherin expression. Importantly, the worst patient survival rate among all GCs analyzed was seen in patients with tumors carrying CDH1 structural alterations, preferentially those belonging to FIGC families. CONCLUSION: CDH1 somatic alterations exist in all clinical settings and histotypes of GC and associate with different survival rates. Their screening at GC diagnosis may predict patient prognosis and is likely to improve management of patients with this disease.
PURPOSE: The prognosis of gastric cancer (GC) is poor, and the molecular pathogenesis players are vastly unknown. Surgery remains the primary option in GC treatment. The aim of this study was to investigate the impact of somatic CDH1 alterations in prognosis and survival of patients with GC. PATIENTS AND METHODS: A series of patients with sporadic and familial GC (diffuse and intestinal; n = 246) were analyzed for somatic CDH1 mutations, promoter hypermethylation, and loss of heterozygosity (LOH) by polymerase chain reaction sequencing. E-cadherin protein expression was determined by immunohistochemistry. Associations between molecular, clinicopathologic, and survival data were analyzed. RESULTS:CDH1 somatic alterations were found in approximately 30% of all patients with GC. Both histologic types of sporadic GC displayed LOH in 7.5%, mutations in 1.7%, and hypermethylation in 18.4% of patients. Primary tumors from hereditary diffuse GC, lacking germline CDH1 alterations, showed exclusively CDH1 promoter hypermethylation in 50% of patients. Familial intestinal GC (FIGC) tumors showed LOH in 9.4% and hypermethylation in 17.0%. CDH1 alterations did not associate with a particular pattern of E-cadherin expression. Importantly, the worst patient survival rate among all GCs analyzed was seen in patients with tumors carrying CDH1 structural alterations, preferentially those belonging to FIGC families. CONCLUSION:CDH1 somatic alterations exist in all clinical settings and histotypes of GC and associate with different survival rates. Their screening at GC diagnosis may predict patient prognosis and is likely to improve management of patients with this disease.
Authors: Hikmat A Al-Ahmadie; Gopa Iyer; Byron H Lee; Sasinya N Scott; Rohit Mehra; Aditya Bagrodia; Emmet J Jordan; Sizhi Paul Gao; Ricardo Ramirez; Eugene K Cha; Neil B Desai; Emily C Zabor; Irina Ostrovnaya; Anuradha Gopalan; Ying-Bei Chen; Samson W Fine; Satish K Tickoo; Anupama Gandhi; Joseph Hreiki; Agnès Viale; Maria E Arcila; Guido Dalbagni; Jonathan E Rosenberg; Bernard H Bochner; Dean F Bajorin; Michael F Berger; Victor E Reuter; Barry S Taylor; David B Solit Journal: Nat Genet Date: 2016-02-22 Impact factor: 38.330
Authors: Winifred Lo; Bin Zhu; Arvind Sabesan; Ho-Hsiang Wu; Astin Powers; Rebecca A Sorber; Sarangan Ravichandran; Ina Chen; Lucas A McDuffie; Humair S Quadri; Joal D Beane; Kathleen Calzone; Markku M Miettinen; Stephen M Hewitt; Christopher Koh; Theo Heller; Sholom Wacholder; Udo Rudloff Journal: J Med Genet Date: 2019-02-11 Impact factor: 6.318
Authors: Rob Noorlag; Pauline M W van Kempen; Cathy B Moelans; Rick de Jong; Laura E R Blok; Ronald Koole; Wilko Grolman; Paul J van Diest; Robert J J van Es; Stefan M Willems Journal: Epigenetics Date: 2014-07-08 Impact factor: 4.528
Authors: Namrata Setia; Jeffrey W Clark; Dan G Duda; Theodore S Hong; Eunice L Kwak; John T Mullen; Gregory Y Lauwers Journal: Oncologist Date: 2015-09-30
Authors: Jiwon Koh; Keun-Wook Lee; Soo Kyung Nam; An Na Seo; Ji-Won Kim; Jin Won Kim; Do Joong Park; Hyung-Ho Kim; Woo Ho Kim; Hye Seung Lee Journal: Oncologist Date: 2019-08-01